About
Treatments for neurobehavioral and neurocognitive disorders
Areas of Focus
Categories
Small Molecule Pharmaceutical
Clinical Trials (4)
View allTotal Trials
4
As Lead Sponsor
4
As Collaborator
0
Total Enrollment
251
By Phase
PHASE3: 1PHASE2: 3
By Status
COMPLETED: 3NOT_YET_RECRUITING: 1
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Today
Hover over trial bars to see details
Recent Trials
NCT05914194Lead Sponsor
A Eight-Week Study of NLS-2 (Mazindol Extended Release) in Participants With Narcolepsy Type 1
PHASE3Not yet recruiting
48 participants
Started: Jul 15, 2024 · Completed: Jul 30, 2025
NCT05055024Lead Sponsor
An Open Label Study of NLS-2 (Mazindol Extended Release) in Subjects With Narcolepsy
PHASE2Completed
52 participants
Started: Oct 26, 2021 · Completed: Jan 19, 2023
NCT04923594Lead Sponsor
Four-week Study of the Safety and Efficacy of NLS-2 (Mazindol Extended Release) in the Treatment of Narcolepsy
PHASE2Completed
67 participants
Started: Sep 13, 2021 · Completed: Jun 30, 2022
NCT02808104Lead Sponsor
Mazindol Controlled Release in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
PHASE2Completed
84 participants
Started: Aug 31, 2016 · Completed: Mar 28, 2017
Locations (1)
Headquarters
Zurich, Switzerland
Map
Loading map...